February 6, 2018 09:24 AM EST
R&D

Eye­ing a block­buster mi­graine mar­ket, Al­ler­gan takes an in­side track on acute cas­es with pos­i­tive PhI­II

John Carroll

Editor & Founder

With a full slate of in­jectable CGRP mi­graine drugs po­si­tion­ing them­selves at the fin­ish line for FDA ap­provals for chron­ic cas­es, Al­ler­gan $AGN to­day took …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times